|View printer-friendly version|
|CytomX Announces U.S. FDA Clearance of Investigational New Drug Application for Phase 1/2 Clinical Study of Anti-PD-L1 Probody Therapeutic, CX-072|
“Initiating the first clinical program emerging from the Probody platform is a major milestone for CytomX,” said
Clinical data from PROCLAIM-072 is expected to begin to emerge in late 2017 and throughout 2018.
Corporate Communications Contact: